Novo Nordisk v. Caraco Pharmaceutical Laboratories, Case No. 11-1223 (Fed. Cir. June 18, 2013)
The Federal Circuit overturned the district court’s determination of inequitable conduct as the asserted omissions and representations submitted in a pair of declarations did not meet the heightened standards of materiality established by recent Federal Circuit opinions.
The Federal Circuit affirmed the district court’s determination that one of the asserted claims was obvious.